StockNews.com Initiates Coverage on Cellectis (NASDAQ:CLLS)

StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS) in a report issued on Wednesday. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Barclays reduced their target price on Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th.

Cellectis Price Performance

NASDAQ:CLLS opened at $1.98 on Wednesday. Cellectis has a 12-month low of $1.70 and a 12-month high of $3.77. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $110.06 million, a P/E ratio of -1.52 and a beta of 3.10. The stock’s fifty day simple moving average is $2.02 and its 200-day simple moving average is $2.25.

Cellectis (NASDAQ:CLLS) last posted its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.03). Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. The company had revenue of $18.05 million during the quarter, compared to the consensus estimate of $5.00 million. During the same quarter in the prior year, the business earned ($0.31) earnings per share. Equities research analysts expect that Cellectis will post -0.46 earnings per share for the current year.

Institutional Trading of Cellectis

Several hedge funds and other institutional investors have recently modified their holdings of the company. Principal Financial Group Inc. raised its stake in shares of Cellectis by 2.9% in the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after purchasing an additional 12,467 shares during the period. XTX Topco Ltd acquired a new stake in shares of Cellectis in the second quarter valued at about $29,000. First Affirmative Financial Network acquired a new stake in shares of Cellectis in the third quarter valued at about $45,000. Finally, Long Focus Capital Management LLC increased its position in shares of Cellectis by 2.9% in the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after acquiring an additional 130,000 shares during the last quarter. Institutional investors and hedge funds own 63.90% of the company’s stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.